在风湿病学中CAR T细胞治疗的障碍
Karolina Lungova1, Michael Putman1
1Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
The Lancet. Rheumatology
|November 8, 2024
概括
化学抗原受体 (CAR) T细胞疗法对类风湿性疾病有希望,但面临挑战. 未来的方法可能会提高治疗狼和硬质皮质症等疾病的疗效和安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞疗法正在成为一种有前途的类风湿性疾病治疗方法,包括全身性红斑狼 (SLE),异常性炎症性肌肉病变和全身性硬化症.
- 许多临床试验正在进行中,这表明人们对这种治疗自身免疫性疾病的治疗方法有很大的兴趣和投资.
研究的目的:
- 评估CAR T细胞治疗在治疗类风湿性疾病中的潜力和挑战.
- 确定广泛采用的障碍,并探索未来的方向,以优化CAR T细胞在风湿病学中的方法.
主要方法:
- 审查目前的临床试验和治疗策略,用于CAR-T细胞治疗的类风湿性疾病.
- 分析现有的CAR T细胞方法的局限性,包括B细胞枯竭的有效性和患者的资格.
- 探索新的CAR T细胞设计,如仿真自身抗体受体和仿真自身抗原T细胞受体.
主要成果:
- 卡尔T细胞疗法显示出显著的前景,但面临着在风湿病学中广泛采用实质性障碍.
- 目前的CAR T细胞策略主要依赖于B细胞枯竭,在不同自身免疫性疾病中成功率可变.
- 关键的挑战包括疾病特异性治疗轨迹,受限的患者资格,高成本和安全问题,如细胞因子释放综合征和感染风险.
结论:
- 虽然CAR T细胞疗法对风湿性疾病有潜力,但目前的方法需要改进.
- 未来的研究应该专注于开发更有针对性的CAR T细胞策略,例如抗原特异性受体,以提高疗效和安全性.
- 优化的CAR T细胞疗法可以为患有自身免疫性风湿性疾病的患者提供改善的治疗结果.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
01:24T Cell Types and Functions
954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117